重组葎草花粉主要变应原免疫特性研究  

Immunological characteristics of the recombinant major pollen allergen pTSX2 of Humulus scandens

作　　者：吴媛媛[1] 孙秀珍[1] 李满祥[1] 刘昀[1] 王贵佐[1] 卢家美[1] 

机构地区：[1]西安交通大学医学院第二附属医院呼吸病研究所,陕西西安710004

出　　处：《南方医科大学学报》2012年第10期1431-1434,共4页Journal of Southern Medical University

基　　金：国家自然科学基金(30371336)~~

摘　　要：目的鉴定重组葎草花粉主要变应原pTSX2的免疫特性,并初步评价其安全性。方法应用Western blotting鉴定pTSX2的免疫特性;ELISA法检测经pTSX2免疫的小鼠血清sIgE、sIgG水平;pTSX2免疫治疗小鼠哮喘模型后:ELISA法测定小鼠血清sIgE、sIgG水平;计数小鼠支气管肺泡灌洗液(BALF)中细胞总数及嗜酸性粒细胞(Eos)比值;ELISA法检测小鼠BALF中及脾组织匀浆中细胞因子(IL-4、IFN-γ)水平;评价小鼠肺组织炎症程度。结果 Western blotting结果显示重组表达的pTSX2可与70%的葎草花粉特异性过敏的变应性哮喘患者血清发生抗原抗体反应;pTSX2免疫正常小鼠后主要诱导产生血清sIgG;pTSX2免疫治疗小鼠哮喘模型后:血清中sIgE、sIgG的抗体水平分别为(146.74±28.57)和(548.76±11.98)μg/ml,与哮喘模型组的(603.06±10.00)和(260.32±6.40)μg/ml相比差异有统计学意义(P<0.05);BALF中细胞总数及Eos百分比与哮喘模型组相比明显下降(P<0.05);BALF中IL-4、IFN-γ水平分别为(56.74±28.57)和(49.7±11.98)pg/ml,与哮喘模型组的(89.03±10.00)和(23.10±6.40)pg/ml相比差异有统计学意义(P<0.05);脾组织匀浆中IL-4、IFN-γ水平分别为(126.24±37.00)和(1547.72±490.43)pg/ml,与哮喘模型组的(457.95±70.06)和(720.34±93.96)pg/ml相比差异有统计学意义(P<0.05);肺组织炎症程度减轻。结论重组葎草花粉主要变应原pTSX2具有较好的免疫治疗作用,且安全性较高,其机制可能是抑制变应原sIgE抗体、诱导变应原sIgG抗体产生,降低气道炎症细胞浸润,调节Thl/Ih2平衡。Objective To identify the immunological characteristics of the recombinant major pollen allergen pTSX2 of Humulus scandens and evaluate its safety in immunotherapy of allergic asthma in mice.Methods Western blotting was used to characterize the immunological properties of pTSX2,and its immunogenicity in normal mice was evaluated by detecting sIgG and sIgE levels.The mouse models of allergic asthma were immunized with pTSX2 and examined for sIgE and sIgG levels,total cells and eosinophils percentage in BALF,interleukin-4（IL-4） and interferon-γ（IFN-γ） levels in BALF and spleen homogenate,and changes in lung pathologies.Results Western blotting showed that pTSX2 reacted with the majority（about 70%） of sera from patients allergic to Humulus pollen.In normal mice,pTSX2 mainly induced the production of sIgG.In mouse models of allergic asthma,intervention with pTSX2 caused a significant reduction of sIgE and an increase of sIgG（P0.05）,significantly decreased the total cells and eosinophils in BALF（P0.05）,obviously lowered IL-4 but increased IFN-γ in BALF and spleen homogenate（P0.05）,and diminished inflammatory cell infiltration and percentage of eosinophils in the lung tissues.Conclusion pTSX2 shows a definite therapeutic effect and safety in the treatment of allergic asthma in mice possibly by inhibiting sIgE and inducing sIgG production,suppressing airway allergic inflammation and regulating the balance between Thl and Th2.

关 键 词：支气管哮喘 葎草花粉变应原 重组变应原 特异性免疫治疗 

分 类 号：R392[医药卫生—免疫学]